

## Fainting symptoms significantly reduced with Buzzy® + new indications to control needle pain with labs, blood donation

Patients who avoid needed medical care due to needle phobia can face their fears - and even reduce fainting risk - with Buzzy.

ATLANTA, GEORGIA, USA, June 1, 2023 /EINPresswire.com/ -- There is new hope for people who struggle with needle procedures. From needle phobia to vasovagal responses (fainting) and difficult vein access, blood work causes anxiety, pain, and



discomfort. Buzzy is a Class 1 medical device with CE marking. The patented, non-combination, needle pain solution used in over 45 million needle procedures has just added new <u>FDA 510(k)</u> <u>indications</u> for use — controlling needle pain for lab draws and blood work.



I would go for lab work, they would stick me multiple times, I would faint-terrible experience. All I want to say is THANK YOU! No more panic, no more fainting, and now they can draw my blood easily."

Maria S., Buzzy customer

A study by the CDC and Duke University presented at the Pediatric Academic Societies meeting in May 2023 reported Buzzy significantly reduced severe symptoms of lightheadedness, nausea, and weakness by 25%.\* The results from this study could expand accessibility to individuals previously deterred from seeking medical care due to a vasovagal response.

"I have always been deadly scared of blood work. I would put off getting physicals because lab work was associated with them. When I would go for lab work, they would stick

me multiple times, I would faint - terrible experience. All I want to say is THANK YOU! No more panic, no more fainting, and now they can draw my blood easily." - Maria S.


Immunology, asthma, and allergy patients, in particular, experience more than their fair share of needle procedures. Adding a monthly, weekly, or even daily shot routine can be especially

disruptive. Buzzy helps with infusion therapy and subcutaneous injections, whether in the hospital or at home.

"Healthcare professionals get used to needles, so they have trouble imagining that a patient might reject lifesaving injections," Dr. Amy Baxter reported. "Some will refuse a superior biologic solution, and some are simply too fatigued from injected or infused treatments to continue. Buzzy helps people get the right treatment and stick with it."

Approximately one in four adults and over 60% of adolescents experience needle fear.\*\* This fear impacts all aspects of healthcare. It prevents people from seeking necessary treatment. It impacts blood banks relying on donations for life-saving procedures. It even impacts the development of life-saving medications like biologics, which rely on plasma donations. With the expanded indications beyond the more general clearances for injections, venipuncture, and IV starts, Pain Care Labs is transforming healthcare practices and empowering medical professionals and patients.

The Company will exhibit from 9 - 11 June at the European Academy of Allergy and Clinical Immunology (
<u>EAACI</u>) Hybrid Congress 2023, in Hamburg, Germany. The EAACI connects physicians and industry





experts with the goal of improving patient outcomes. Pain Care Labs is currently expanding Buzzy into clinical practices via patient support starter kit initiatives and tailored product launches.

Buzzy needle solutions are available around the world for at-home or in-clinic use through the Company's global network of <u>international distribution partners</u>.

## ABOUT PAIN CARE LABS

Pain Care Labs is the industry leader in non-invasive pain relief solutions. Established in 2006 by emergency physician and pain researcher Amy Baxter MD, the Company is dedicated to effective, reusable, affordable solutions to pain. Buzzy®, the flagship product, has been used to block the pain from over 45 million needle procedures. VibraCool® is an FDA-cleared device for relief of muscle or tendon aches and to treat myofascial pain caused by trigger points, restricted motion, and muscle tension. The Company's award-winning solutions are supported by over 80 independent clinical trials. The patented M-Stim® neuromodulation platform gives serious, simple relief. Pain Care Labs was named "Industry Leader for Localized Pain Relief" by Frost & Sullivan, the most prestigious medical device consulting firm. For more information visit PainCareLabs.com.

\*https://resources.paincarelabs.com/hubfs/00.%20Documents/PR%20REFERENCE%20FILES/Preventing%20Vasovagal%20Syncope.pdf

https://resources.paincarelabs.com/hubfs/00.%20Documents/PR%20REFERENCE%20FILES/PAS% 202023%20buzzy%20presyncope.pdf

Smith M, Walter EB et al. Preventing Post-Vaccination Presyncope and Syncope in Adolescents Using Simple, Clinic-based Interventions. 2023 Pediatric Academic Soc. Washington, DC. (A) <a href="https://clinicaltrials.gov/ct2/show/NCT04772755">https://clinicaltrials.gov/ct2/show/NCT04772755</a>

\*\*https://pubmed.ncbi.nlm.nih.gov/22617633/

Raven Wilson Pain Care Labs +1 877-805-2899 email us here

Visit us on social media:

Facebook

**Twitter** 

LinkedIn

Instagram

YouTube

TikTok

This press release can be viewed online at: https://www.einpresswire.com/article/636751019

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.